A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

By Abdul Razak A. R.   Soulires D.   Laurie S. A.   Hotte S. J.   Singh S.   Winquist E.   Chia S.   Le Tourneau C.   Nguyen-Tan P.- F.   Chen E. X.   Chan K. K.   Wang T.   Giri N.   Mormont C.   Quinn S.   Siu L. L.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 761-769

Oxford University Press

Access to resources Recommend Favorite

Cost‐Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma

By  

The Oncologist, Vol. 23, Iss. 2, 2018-02 ,pp. : 225-233

John Wiley & Sons Inc

Access to resources Recommend Favorite

Salvage surgery as the primary treatment for recurrent oral squamous cell carcinoma

By Lin Y.-C.   Hsiao J.-R.   Tsai S.-T.  

Oral Oncology, Vol. 40, Iss. 2, 2004-02 ,pp. : 183-189

Elsevier

Access to resources Recommend Favorite

Phase I/II study of docetaxel, cisplatin and S1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma

By                      

Oncology Letters, Vol. 4, Iss. 5, 2012-01 ,pp. : 898-904

Spandidos Publications

Access to resources Recommend Favorite

Evaluation of the Combination of Docetaxel/Carboplatin in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN): A Southwest Oncology Group Phase II Study

By Samlowski Wolfram E.   Moon James   Kuebler J. Philip   Nichols Craig R.   Gandara David R.   Ozer Howard   Williamson Stephen K.   Atkins James N.   Schuller David E.   Ensley John F.  

Cancer Investigation, Vol. 25, Iss. 3, 2007-04 ,pp. : 182-188

Informa Healthcare

Access to resources Recommend Favorite